Blood Test for Early Cancer Detection Falls Short in Landmark NHS Trial
The NHS-Galleri MCED trial missed its primary endpoint but showed promising reductions in stage IV cancers and more early-stage detections.
Summary
A large UK trial testing a multicancer early detection blood test found it did not significantly reduce late-stage cancer diagnoses across 12 tumor types. The NHS-Galleri trial enrolled nearly 143,000 adults aged 50-77 and randomly assigned them to receive the Galleri blood test plus standard care or standard care alone. While the primary endpoint — reducing stage III and IV cancers — was not met, researchers observed a 14% reduction in stage IV cancers specifically and a 16% increase in stage I and II cancer detection. ASCO's chief medical officer stated the test is not yet ready for screening guidelines, though researchers believe longer follow-up may reveal stronger mortality benefits.
Detailed Summary
Multicancer early detection blood tests represent one of the most anticipated frontiers in cancer prevention, promising to catch tumors before they spread. The NHS-Galleri trial is the largest randomized study to date testing whether such a test can shift cancer diagnoses toward earlier, more treatable stages — a goal directly tied to reducing cancer mortality.
The trial enrolled 142,924 asymptomatic adults aged 50 to 77 in England, randomized equally to receive the Galleri liquid biopsy test alongside standard care or standard care alone, across up to three annual screening rounds. The 12 cancer types studied — including lung, pancreas, ovary, and esophagus — are among those with no current population-level screening tools, collectively responsible for the majority of cancer deaths.
The primary endpoint — a reduction in stage III and IV cancers combined — was not met, with a nonsignificant 3% increase in the intervention arm. However, secondary findings were more encouraging: stage IV cancers specifically fell by 14% over three rounds, with reductions deepening to 22% and 26% in the second and third rounds respectively. Stage I and II cancer detection rose by 16%, suggesting the test is identifying cancers earlier even if late-stage incidence has not yet dropped significantly.
Researchers interpret the deepening stage IV reductions as a signal that extended follow-up may eventually demonstrate a statistically meaningful survival benefit. The biology of cancer screening means mortality improvements often lag detection shifts by years, and this trial may simply need more time.
Despite this, ASCO's chief medical officer was clear: the Galleri test should not yet enter cancer screening guidelines. Liquid biopsies remain validated for monitoring known cancers, not population-level early detection. For health-conscious individuals, this trial is a reminder that even promising technologies require rigorous evidence before adoption, and that standard screening for colorectal, lung, and breast cancers remains the highest-value action available today.
Key Findings
- MCED blood test did not significantly reduce combined stage III/IV cancers across 12 tumor types after 3 rounds.
- Stage IV cancers specifically dropped 14% overall, with reductions growing to 26% by the third screening round.
- Stage I and II cancer detection increased by 16%, suggesting the test shifts some diagnoses to earlier stages.
- ASCO does not recommend liquid biopsies for population cancer screening based on current evidence.
- Longer follow-up is needed to determine whether early detection shifts translate into reduced cancer mortality.
Methodology
This is a meeting coverage news report from MedPage Today summarizing results presented at the ASCO 2026 annual meeting. The underlying evidence is a large randomized controlled trial (n=142,924) — the NHS-Galleri trial — representing high-quality evidence, though full peer-reviewed publication has not yet been cited. Source credibility is high; MedPage Today is a respected medical news outlet covering clinician-level research.
Study Limitations
Full peer-reviewed data from the NHS-Galleri trial have not yet been published, limiting independent verification of statistical analyses. The trial has not yet reported cancer mortality outcomes, which are the definitive measure of screening benefit. Coverage is based on a press conference presentation, and complete methodology details, subgroup analyses, and false-positive rates require primary source review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.